The results of the Endometriosis Priority Setting Partnership, led by Andrew Horne and Philippa Saunders from the University of Edinburgh, and overseen by the James Lind Alliance—a non-profit initiative funded by the National Institute for Health Research— were published in the Lancet (attached) with a commentary in the BMJ (attached), and highlighted in the National Press (see link below).
Patients and clinicians agreed that improving the diagnosis of endometriosis and stopping its progression are key research priorities for the condition.
Leonard R, Adamson D, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE, Anderson RA, Anglo Celtic Collaborative Oncology Group. (2 May, 2017)
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. doi: 10.1093/annonc/mdx184.
This large RCT across the UK assessed the potential for GnRH agonist treatment to provide ovarian protection during chemotherapy for breast cancer. OPTION confirmed that there is a benefit, with fewer women having premature ovarian insufficiency with GnRH agonist treatment. This was only seen in women under 40 and the benefit in terms of the amount of ovarian function saved was small, however this may provide a valuable approach for younger women at risk of fertility loss from breast cancer treatment.